Italia markets closed

Aptose Biosciences Inc. (LTI.F)

Frankfurt - Frankfurt Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
1,0600-0,0600 (-5,36%)
Alla chiusura: 08:04AM CEST
Schermo intero
Chiusura precedente1,1200
Aperto1,0600
Denaro1,1400 x N/D
Lettera1,1500 x N/D
Min-Max giorno1,0600 - 1,0600
Intervallo di 52 settimane1,0600 - 7,3800
Volume6
Media Volume51
Capitalizzazione18,235M
Beta (5 anni mensile)1,42
Rapporto PE (ttm)N/D
EPS (ttm)-7,0700
Prossima data utili06 mag 2024 - 10 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference

    Company to Hold Clinical Update Webcast; Details ForthcomingSAN DIEGO and TORONTO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that two abstracts on tuspetinib, Aptose’s Phase 1/2 myeloid kinase inhibitor in development for acute myeloid leukemia (AML), have been accepted for post

  • GlobeNewswire

    Aptose to Present at the Cantor Global Healthcare Conference

    SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the Cantor Global Healthcare Conference being held September 26-28, 2023, in New York City. Dr. William G. Rice, Chairman, President and CEO of Aptose, will part

  • GlobeNewswire

    Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical

    — TUS/VEN doublet continues safe and effective in AML patients who failed prior venetoclax —SAN DIEGO and TORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced closing of a $3 million investment in common shares of the Company (the “Shares”) as the first tranche of a private equity